Use of delta opioid receptor antagonists to treat immunoregulato

Details Use of delta opioid receptor antagonists to treat immunoregulato Use of delta opioid receptor antagonists to treat immunoregulato

1993-11-08

1995-11-07

Hollrah, Glennon H.

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Having -c-, wherein x is chalcogen, bonded directly to...

514305, 546 37, 546133, A61K 31445, C07D22102, C07D47102, C07D45300

Patent

active

054648416

ABSTRACT:
A therapeutic method is provided to elevate a depressed mammalian autologous mixed lymphocyte response and to alleviate the diseases associated therewith by the administration of an effective amount of certain selective delta opioid receptor antagonists to a mammal such as a human patient in need of such treatment.

REFERENCES:
patent: 4816586 (1989-03-01), Portoghese et al.
patent: 5244904 (1993-09-01), Nagase et al.
patent: 5332818 (1994-07-01), Nagase et al.
T. Akami et al., Transplantation Proceedings, 24, 485 (1992).
K. Arakawa et al., "Delta Opioid Receptor Antagonist for Immunosuppression after Rat Kidney Transplantation", Abstract and Poster #18, Fifty-fourth Annual Scientific Meeting of the International Narcotics Research Conference, Jun. 23-27 (1992).
K. Arakawa et al., Transplantation, 53, 951 (1992) is cited in the specification at p. 2, line 31.
K. Arakawa, et al., Transplant, 24, 696 1992) is cited in the specification at p. 2, line 31.
R. Cotton et al., Eur. J. Pharmacol., 97, 331 (1984) is cited in the specification at p. 1, line 23, p. 2, line 27.
W. E. Crowe et al., Arth. Rheum., 28, 537 (1985) is cited in the specification at p. 3, lines 11 and 23.
Cytomegalovirus-Biology and Infection, M. Ho., ed., Plenum, NY (1982) at pp. 223-243 is cited in the specification at p. 10, line 13.
E. C. Ebert et al., Clin. Immunol. Immunopathol., 37, 283 (1985) is cited in the specification at p. 10, line 16.
R. E. Faith et al., NIDA Res. Monogr., 54, 300 (1984) is cited in the specification at p. 2, line 6. (I).
R. E. Faith et al., Ann. N.Y. Acad. Sci., 496, 137 (1987) is cited in the specification at p. 2, line 9. (II).
J. C. Froelich et al., Alcoholism Clin. and Exp. Res., Abstract 20, p. 315 (1991) is cited in the specification at p. 1, line 31.
S. Gupta et al., Vox Sang., 44, 265 1983) is cited in the specification at p. 10, lines 6, 9 and 10.
J. K. Gutowski et al., Immunol. 46, 801 (1982) is cited in the specification at p. 11, lines 1 and 3.
D. A. Hafler et al., Clin. Immunol. and Immunopathol., 58, 115 (1991) is cited in the specification at p. 10, line 7 and 35.
D. A. Hafler et al., Immunol. Today, 10, 104 (1989) is cited in the specification at p. 10, line 20.
T. Han et al., Blood, 60, 1075 (1982) is cited in the specification at p. 10, line 18.
R. L. Hirsch, Clin. Exp. Immunol., 64, 107 (1986) is cited in the specification at p. 3, line 22 and at p. 10, line 4.
M. Hendrickson et al., Journal of Burn Care and Rehabilitation, 10, 494 (1989).
B. D. Jankovic et al., Ann. N.Y. Acad. Sci., 540, 691 (1988) is cited in the specification at p. 2, line 26.
D. Kelleher et al., Gut, 30, 839 (1989) is cited in the specification at p. 10, line 35.
M. M. Kuntz et al., J. Exp. Med., 143, 1042 (1976) is cited in the specification at p. 3, line 14.
A. Laffon et al., Rheumatol. Int., 3, 117 (1983) is cited in the specification at p. 10, line 5 and p. 11, line 12.
D. Maric et al., Ann. N.Y. Acad. Sci. 496 126 (1987) is cited in the specification at p. 2, line 13.
W. R. Martin, Pharmacol. Rev., 35, 283 (1983) is cited in the specification at p. 1, line 14.
D. R. Oleson et al., Brain, Behavior and Immun., 2, 171 (1988) is cited in the specification at p. 2, line 14.
Prakash et al., Cell. Immunol., 112, 64 1988) is cited in the specification at p. 11, line 1.
P. S. Portoghese et al., J. Med. Chem., 31, 281 (1988) is cited in the specification at p. 5, lines 3 and 7.
P. S. Portoghese et al., J. Med. Chem., 33, 1547 (1990) is cited in the specification at p. 5, line 6.
P. S. Portoghese et al., Eur. J. Pharmacol., 146, 185 (1988) is cited in the specification at p. 5, line 7.
Abdelhamin et al. J. Pharmacol. Exp. Ther., 258, 299 (1991) is cited in the specification at p. 5, line 8.
J. W. Shaw et al., Life Sci., 31, 1259 (1982) is cited in the specification at p. 1, line 22.
J. S. Smolen et al., J. Clin. Invest., 68, 1601 (1981) is cited in the specification at p. 3, line 16.
M. Sofouglu et al., J. Pharmacol. Exp. Ther., 257, 676 (1991) is cited in the specification at p. 1, line 32.
N. Talal et al., Behring Inst. Mitt., 72, 169 (1983) is cited in the specification at p. 12, line 3.
D. D. Taub et al., PNAS USA, 88, 360 (1991).
M. E. Weksler et al., J. Exp. Med., 146, 1833 (1977) is cited in the specification at p. 3, line 15.
J. Wybran et al., J. Immunol., 123, 1068 (1979) is cited in the specification at p. 2, line 5.

Affiliated with

Also associated with

Rating

Use of delta opioid receptor antagonists to treat immunoregulato does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Use of delta opioid receptor antagonists to treat immunoregulato, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use of delta opioid receptor antagonists to treat immunoregulato will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-197454